Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing an important role in the strategic change taking place in the space. “It’s a fairly clever service and approach that I think will create, not just an […]
Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin […]
Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported. Get the full story at our sister site, Drug Delivery Business News.
Artificial pancreas developer Bigfoot Biomedical said today that it acquired Patients Pending and its connected insulin pen technology for an undisclosed amount. With this acquisition, Bigfoot said it is the 1st company to simultaneously pursue both insulin infusion and injection delivery solutions. Get the full story at our sister site, Drug Delivery Business News.
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at MassDevice’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent […]
Over 50 years ago, scientists discovered the ability to externally control blood glucose regulation for individuals with type 1 diabetes. Since then, researchers in the field of diabetes management have dreamt of creating a closed-loop system – a combined glucose sensor, control algorithm and insulin infusion device – to effectively act as an “artificial pancreas” […]
The Juvenile Diabetes Research Foundation said today that its T1D Fund made an unspecified equity investment in Bigfoot Biomedical and the Smartloop automated insulin delivery system it’s developing. “We are thrilled to have a fund associated with the world’s largest nonprofit funder of [Type I diabetes] research as an investor,” Bigfoot president & CEO Jeffrey Brewer […]
Bigfoot Biomedical said yesterday that it raised $35.5 million in a Series A round for the artificial pancreas technology it’s developing to treat Type I diabetes. The round, led by Quadrant Capital Advisors, included backing from Cormorant Asset Management, Senvest Capital, and Visionnaire Ventures. Bigfoot said it plans to use the proceeds to fund the final development of […]
Bigfoot Biomedical is launching a clinical trial of its Smartloop automated insulin delivery system at medical centers in California and Colorado. The Milpitas, Calif.-based company said it has enrolled its 1st patients in a trial of its Smartloop device that will be conducted at three sites: Stanford University School of Medicine (working with Lucile Packard Children’s […]
Bionic pancreas developer Bigfoot Biomedical raised $2.4 million in a new round of debt financing, according to an SEC filing posted yesterday. The company, while staying mostly under the radar, is developing a closed-loop device combo that would continuously monitor glucose levels and deliver insulin based on a proprietary algorithm. The now Milpitas, Calif.-based medical […]
Bigfoot Biomedical, developers of an artificial pancreas, raised $3.8 million in a debt funding round, according to an SEC filing. The money comes from 3 unnamed investors and Bigfoot Biomedical has not disclosed what the funds will be used for. The company is looking to raise $5 million for the round, still seeking an additional […]